Clinical trial · Observational
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
Patient Preferences of Treatment for the Patients Suffering From Muscle-invasive Urothelial Carcinoma of Bladder Following Radical Cystectomy in Japan
NCT05742867CI-TRIAL-00085000SNUGGLEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to identify important treatment attributes for post-radical cystectomy (RC) treatment for participants with MIBC (Muscle-Invasive Bladder Cancer) and assess the relative importance of treatment attributes for post-RC treatment in Japan.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urinary Bladder Neoplasms | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Cohort 1
- description
- High-risk Muscle-Invasive Bladder Cancer (MIBC) participants following radical cystectomy
Primary outcomes (11)
- measure
- Overall survival
- timeFrame
- Up to 1 year after radical cystectomy
- description
- Median overall survival (years)
- measure
- 5-year survival rate
- timeFrame
- Up to 1 year after radical cystectomy
- description
- Defined as the percentage of patients that are alive after 5 years
- measure
- Disease-free survival (DFS)
- timeFrame
- Up to 1 year after radical cystectomy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must reside in Japan and able to speak/read Japanese for the interview/survey * Must have a clinical diagnosis of Muscle-invasive bladder cancer (MIBC): * ypT2-ypT4a or ypN+ MIBC, with prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy * pT3-pT4a or pN+ MIBC, without prior neoadjuvant cisplatin chemotherapy and underwent radical cystectomy * Must not have received any treatment related to MIBC after radical cystectomy Exclusion Criteria: * Determined by the physician as being unsuitable for the study (e.g. having any clinically significant psychiatric disorder, cognitive impairment, or having difficulty with communicating in Japanese) * Confirmed diagnosis of other primary cancers at the time of obtaining consent * Current participation in a MIBC clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.